About THOR Photomedicine

On Star Trek, when someone is injured, they are taken to sick bay where the doctor uses a low-intensity laser to heal the patient instantly. We make those (just not quite as fast as on TV).

The treatment, called Photobiomodulation (PBM Therapy), previously known as Low-Level Laser Therapy (LLLT), is considered by many scientists to be "a new branch of medicine".

Light (within certain parameters) can regenerate tissue, reduce inflammation and reduce pain. It does this by increasing cellular energy and reducing oxidative stress. These effects have been tested in over 1,800 clinical trials (RCTs) and thousands of laboratory studies, and have been published in leading journals, including The Lancet, BMJ, Nature, PNAS, Spine, Muscle and Nerve, Pain, Retina and Stroke.

Dedicated private PBM clinics are being born every month to meet public demand for pain relief, and the former head of tissue viability for Scotland, Lydia Jack, demonstrated that the laser paid for itself with the first patient she treated.

Already, THOR has over 5,000 customers in pioneering clinics and hospitals across more than 70 countries, and is the only company with FDA, CE, TGA, and NATO clearance. We are also listed on GSA and eCAT in the United States for government purchases.

VISION

Photobiomodulation (PBM) in every department of every hospital.

MISSION

To heal and relieve pain.

VALUES

Our decisions and actions must work for all stakeholders;

• Customers & patients
• Suppliers
• Employees and their families
• Shareholders
• Our community and the rest of humankind
• Professional, honest and fair in all our dealings

OBJECTIVE

To establish Photobiomodulation as a standard of care for
10 diseases in
10 countries in
10 years (end of 2030)

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

[top]